August 22, 2024 08:00 AM EDT
Financing
Startups
Pharma

Ver­sant and No­var­tis build 'Chi­nook 2.0' for RNA ther­a­pies in kid­ney dis­eases

Kyle LaHucik

Senior Reporter

Five years to the day af­ter launch­ing Chi­nook Ther­a­peu­tics, Ver­sant Ven­tures is back with a sec­ond gen­er­a­tion of that kid­ney dis­ease biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Bad trip: How cul­ture con­flict and a need for cash near­ly broke Lykos

Cigna sues FTC, call­ing for with­draw­al of 'bi­ased, er­ro­neous' PBM re­port

Af­ter land­ing a key win in a com­mon can­cer con­di­tion, Pfiz­er faces a big test in Phase 3

No­var­tis’ Kisqali snags FDA ap­proval to re­duce re­cur­rence in pa­tients with ear­ly forms of breast can­cer

23andMe heads to ES­MO to tout its two clin­i­cal-stage drugs af­ter scrap­ping dis­cov­ery team

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times